Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Q2 2016 Earnings Presentation
21 slides from Halozyme Therapeutics's earnings presentation, Aug 9, 2016
Slide 1: Second Quarter 2016 Earnings Call
Second Quarter 2016 Earnings Call August 9, 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include future product development and regul
Slide 3: Two-Pillar Strategy For Growth
Two-Pillar Strategy For Growth ENHANZE™ Platform PEGPH201 Platform Licensing/Royalty Agreements Based On Investigational New Oncology Drug Proprietary Enzyme, rHuPH20 Studying Pan-tumor Potential O H N O CH2 CH2 O CH2 H3 C n O H N O O CH2 CH2 O CH2 n N H3 C H CH2 CH2 CH2 O O nCH3 O N H O O CH2 CH2 O
Slide 4: PEGPH20 Goal: Improve Targeting Of Co-Administered Cancer Therapies
PEGPH20 Goal: Improve Targeting Of Co-Administered Cancer Therapies 3
Slide 5: HALO 202 Pancreatic: Stage 1 PFS Results With Ventana Companion Diagnostic
HALO 202 | Pancreatic: Stage 1 PFS Results With Ventana Companion Diagnostic Bullock, et. al. “Final Analysis of Stage 1 Data" American Society of Clinical Oncology (ASCO) Annual Meeting 2016. 4
Slide 6: HALO-301 Pancreatic: Enrollment Ongoing
HALO-301|Pancreatic: Enrollment Ongoing Metastatic PEGPH20 + ABRAXANE® + PDA gemcitabine (PAG) Primary Endpoints: Progression-Free High-HA Survival (PFS) patients Overall Survival (OS) ABRAXANE® + gemcitabine N=420 (AG) + placebo • Randomized (2:1 PAG:AG), double-blind, placebo-controlled, global •
Slide 7: Studying Pan-Tumor Potential of PEGPH20
Studying Pan-Tumor Potential of PEGPH20 PEGPH20 Trials Preclinical Phase 1 Phase 2 Phase 3 In Combination With Tumor Gemcitabine and Pancreatic nab-Paclitaxel Cancer (Abraxane®) Gastric Pembrolizumab Cancer / (Keytruda®) NSCLC Eribulin Breast (Halaven®) Cancer with Eisai • PRIMAL study in NSCLC disc
Slide 8: Oncology Pipeline Update
Oncology Pipeline Update 7
Slide 9: PEG-ADA2 Immune Checkpoint Inhibitor
PEG-ADA2 Immune Checkpoint Inhibitor Adenosine: Attractive immune checkpoint target • Abnormally high levels accumulate in the tumor microenvironment • Binds to receptor checkpoints on immune cells AMP Adenosine CD73 • Contributes to an immunosuppressive tumor ATP CD39 microenvironment ATP PEG-ADA2:
Slide 10: HTI-1511 Anti-EGFR Antibody Drug Conjugate
HTI-1511 Anti-EGFR Antibody Drug Conjugate ADC overcomes mutation resistance and selectively kills tumor cell ADC = antibody-drug conjugate HTI-1511: Anti-EGFR Antibody Drug Conjugate • Engineered monoclonal antibody with attenuated binding to human skin grafts ADC • ADC mechanism targets KRAS- or B
Slide 11: ENHANZE Technology
ENHANZE™ Technology 10
Slide 12: ENHANZE: Our Novel Delivery Platform
ENHANZE: Our Novel Delivery Platform Potential Benefits: • Facilitate transition of IV therapies to subcutaneous administration • Reduce multiple injections • Enable large volume of biologics to be delivered subcutaneously • Reduce time required for drug administration • Life cycle management, inclu
Slide 13: ENHANZE: Our Novel Delivery Platform
ENHANZE: Our Novel Delivery Platform US / Partner Target Preclinical Phase 1 Phase 2/3 Approved OUS Herceptin SC OUS Mabthera SC OUS Perjeta SC -- HYQVIA US HYQVIA1 OUS Daratumumab -- Rivipansel -- Phase 1 Complete Bococizumab -- Humira -- 3 Targets -- Identified 1) HYQVIA approved for primary immun
Slide 14: ENHANZE Momentum: Partnerships Accelerating, Royalty Pipeline Building
ENHANZE Momentum: Partnerships Accelerating, Royalty Pipeline Building • Time from deal signing to clinic accelerating • 4 active Phase 1 Studies underway in new products • Phase 3 Study ongoing for HYQVIA CIDP indication • Phase 1 Study recently completed with Pfizer’s Rivipansel 2006 2007 2012 201
Slide 15: Roche Update: SC Conversion Rates
Roche Update: SC Conversion Rates1 1) Information provided during Roche investor update (Jul. 21, 2016). 14
Slide 16: Financial Update
Financial Update 15
Slide 17: Second Quarter 2016 Financial Highlights
Second Quarter 2016 Financial Highlights1 $ U.S. in Millions (unaudited) 2Q 2016 2Q 2015 % Change Total Revenue $33.3 $43.4 (23%) Royalty Revenue $12.3 $6.4 92% Bulk rHuPH20 Sales $9.5 $8.2 16% Hylenex® Recombinant $4.2 $4.2 0% Collaboration Revenue2 $7.4 $24.7 (70%) 1) Dollar amounts and percentage
Slide 18: Second Quarter 2016 Financial Highlights
Second Quarter 2016 Financial Highlights1 $ U.S. in Millions, except EPS (unaudited) 2Q 2016 2Q 2015 % Change Total Revenue $33.3 $43.4 (23%) Total Operating Expense $55.1 $39.2 41% Cost of Product Sales $8.3 $8.1 2% R&D Expense $35.5 $21.2 68% SG&A Expense $11.2 $9.8 14% Net Income / (Loss) ($26.9)
Slide 19: 2016 Financial Guidance
2016 Financial Guidance Previous Updated August 2016 Revenue $130M to $145M $140M to $150M Operating Expenses $245M to $260M $245M to $260M Cash Flow $45M to $65M $65M to $85M Year-end Cash1 $170M to $190M $170M to $190M 1) Year-end cash guidance was increased from Q1 2016 guidance range on Jun. 8,
Slide 20: Value Enhancing Milestones Throughout 2016
Value Enhancing Milestones Throughout 2016 Goal Target Date Initiate HALO-301|Pancreatic trial Complete ✓ Initiate HALO-Eisai Study in Breast Cancer Patients Complete ✓ Advance to Dose Expansion Phase in KEYTRUDA Q4 2016 Study Project reporting mature data from HALO 202 | Q4 2016 Pancreatic Seek new
Slide 21: Second Quarter 2016 Earnings Call
Second Quarter 2016 Earnings Call August 9, 2016
Halozyme Therapeutics — Q2 2016 Earnings Presentation on 6ix